Last reviewed · How we verify
NCT07509372
Evaluation of the Predictive Impact of Serum S100B and S100B Polymorphisms on Postoperative Cognitive Dysfunction and Delirium
trial testing Perioperative Assessment in Postoperative Cognitive Dysfunction in 137 participants. Completed in 6 November 2024.
6 November 2024
Quick facts
| Lead sponsor | Ankara University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 137 |
| Start date | 27 September 2023 |
| Primary completion | 6 November 2024 |
| Estimated completion | 6 November 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Perioperative Assessment
Conditions studied
- Postoperative Cognitive Dysfunction — all drugs for Postoperative Cognitive Dysfunction →
- Delirium, Postoperative — all drugs for Delirium, Postoperative →
Sponsor
Ankara University
Who can join
Adults 18 to 120, any sex, with Postoperative Cognitive Dysfunction or Delirium, Postoperative. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Postoperative cognitive disorders, including postoperative cognitive dysfunction (POCD) and postoperative delirium (POD), are common complications following surgery and anesthesia, particularly in vulnerable patient populations. These conditions are associated with increased morbidity, prolonged hospitalization, and higher healthcare costs. Early identification of patients at risk remains challenging, and reliable biomarkers are needed to improve perioperative risk stratification. S100B protein has been proposed as a biomarker of neuronal injury and blood-brain barrier dysfunction. In addition, genetic variations in the S100B gene may influence individual susceptibility to postoperative cognitive impairment. The aim of this prospective cohort study is to evaluate the association between perioperative serum S100B levels, S100B gene polymorphisms, and postoperative cognitive disorders. Furthermore, the predictive value of perioperative changes in S100B levels for postoperative cognitive dysfunction and delirium will be investigated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07509372
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Postoperative Cognitive Dysfunction
Currently open trials in the same condition.
- NCT07113483 — Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Surgery · Phase 3 · recruiting
- NCT07452367 — Optic Nerve Sheath Diameter and Cognitive Outcomes in Bentall Surgery · recruiting
- NCT07000461 — Transcranial Doppler as a Predictor of Postoperative Cognitive Dysfunction Following Cardiopulmonary Bypass · recruiting
- NCT06689137 — Effects of Dexmedetomidine on Postoperative Neurocognitive Disorder · active not recruiting
- NCT06658769 — Use of Transcranial Magnetic Stimulation in the Post-Operative Cognitive Dysfunction in Elderly · NA · recruiting
Other Ankara University trials
Trials by the same sponsor.
- NCT07441837 — Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients · Phase 2 · not yet recruiting
- NCT07536490 — Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease · not yet recruiting
- NCT06959433 — Lu-177 PSMA Treatment in Cell Renal Carcinoma · Phase 3 · not yet recruiting
- NCT07513272 — EFFECT OF BALLS ON PAIN AND ANXIETY DURING VENIPUNCTURE IN CHILDREN · NA · not yet recruiting
- NCT07536542 — Effects of Dual-Task Training on Upper Extremity Function in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07509372 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara University
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07509372.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing